PIMA525057

TPMT Monoclonal Antibody (OTI2A2), Invitrogen™

Manufacturer: Thermo Scientific

Select a Size

Pack Size SKU Availability Price
Each of 1 PIMA525057-Each-of-1 In Stock ₹ 52,198.50

PIMA525057 - Each of 1

₹ 52,198.50

In Stock

Quantity

1

Base Price: ₹ 52,198.50

GST (18%): ₹ 9,395.73

Total Price: ₹ 61,594.23

Antigen

TPMT

Classification

Monoclonal

Concentration

0.73 mg/mL

Formulation

PBS with 1% BSA, 50% glycerol and 0.02% sodium azide; pH 7.3

Gene Accession No.

P51580

Gene Symbols

TPMT

Immunogen

Full length human recombinant protein of TPMT produced in HEK293T cell

Quantity

100μL

Primary or Secondary

Primary

Target Species

Human

Product Type

Antibody

Isotype

IgG1

Applications

Immunocytochemistry, Immunohistochemistry (Paraffin), Western Blot

Clone

OTI2A2

Conjugate

Unconjugated

Gene

TPMT

Gene Alias

AW106912; HGNC:12014; S-adenosyl-L-methionine:thiopurine S-methyltransferase; thiopurine methyltransferase; Thiopurine S-methyltransferase; TPMT; TPMTD; truncated thiopurine methyltransferase

Host Species

Mouse

Purification Method

Affinity Chromatography

Regulatory Status

RUO

Gene ID (Entrez)

7172

Content And Storage

-20° C, Avoid Freeze/Thaw Cycles

Form

Liquid

Related Products

Img

Thermo Scientific

PIMA525074

--

Img

Thermo Scientific

PIMA525531

--

Img

Thermo Scientific

PIMA525530

--

Img

Thermo Scientific

PIMA525442

--

Img

Thermo Scientific

PIMA525476

--

Img

Thermo Scientific

PIMA524949

--

Img

Thermo Scientific

PIMA525591

--

Img

Thermo Scientific

PIMA525051

--

Description

  • Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine
  • Defects in TPMT are the cause of thiopurine S-methyltransferase deficiency (TPMT deficiency)
  • TPMT is an enzyme involved in the normal metabolic inactivation of thiopurine drugs
  • These drugs are generally used as immunosupressants or cytotoxic drugs and are prescribed for a variety of clinical conditions including leukemia, autoimmune disease and organ transplantation
  • Patients with intermediate or no TPMT activity are at risk of toxicity after receiving standard doses of thiopurine drugs and it is shown that inter-individual differences in response to these drugs are largely determined by genetic variation at the TPMT locus.